Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

o adequate exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

--Tables to follow--

CV THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS DATA

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

Revenues:

Product sales, net $25,
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... developed by researchers at the USC Viterbi School ... a 3-D microfluidic system quickly and cheaply by ... , Microfluidic systems are used in many fields ... small volumes of fluids for use in applications ... clinical diagnostic testing, and synthetic chemistry. Traditionally, microfluidic ...
(Date:9/22/2014)... discovered a way to create a highly sensitive chemical ... The imperfections have unique electronic properties that the researchers ... gas molecules by 300 times. , The study is ... Communications . , Amin Salehi- Khojin, asst professor of ... Asadi, graduate student and Bijandra Kumar, post doc where ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 ... and chitosan are natural biopolymers available in abundance ... from easily available resources such as shells of ... chitosan is mainly due to the high percentage ... Chitosan finds application in various industries owing to ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Graphene imperfections key to creating hypersensitive 'electronic nose' 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3
... successful debut at the Medical Design & Manufacturing East Show. , ... ... of Zeus, Inc., made a successful debut at the Medical Design & ... Convention Center in New York. , , ,"The MD&M East show ...
... has published a white paper titled “Avanta ... Advanced Ceramic Nanopowders” online. This white paper ... powders on a nanometer scale, as well ... of products. Advanced ceramic nanopowders are critical ...
... The U.S. Food and Drug,Administration (FDA) ... to recommend the approval of tolvaptan, Otsuka ... patients with hyponatremia., "Otsuka is pleased ... approval of tolvaptan, an investigational selective,V2-vasopressin receptor ...
Cached Biology Technology:Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2
(Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
(Date:9/23/2014)... welfare consequences of removing infant chimpanzees from their mothers ... impacts of this type of early life experience. In ... 60 chimpanzees and concluded that those who were removed ... humans as pets or performers are likely to show ... research project, published today in the open-access journal ...
(Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
Breaking Biology News(10 mins):Eating five a day may keep the blues away 2Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Answer to restoring lost island biodiversity found in fossils 2
... Mental disorders, such as depression, anxiety disorders, addiction ... care systems around the world. In the EU alone, ... this corresponds to 83 Million citizens suffer from ... in the EU as the most disabling disorder of ...
... researchers at The Medical College of Wisconsin, in Milwaukee, ... how a synthetic chemical mimics abscisic acid (ABA), a ... environmental conditions such as drought. The results are published ... in advance of print publication later. For years scientists ...
... twin awards from the National Science Foundation (NSF) totaling ... Computational Sciences (NICS) will add 300 teraflops to the ... have access to more than 200 million additional service ... available from NICS to over 800 million and benefitting ...
Cached Biology News:23rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 223rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 323rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 423rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 523rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 623rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 723rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 823rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 923rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 1023rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 11Growing drought-tolerant crops inching forward 2NICS to add more than 300 Teraflops to the NSF’s computing capacity 2
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: